

**BUTALBITAL, ACETAMINOPHEN, CAFFEINE- butalbital, acetaminophen, and
caffeine tablet
Asclemed USA, Inc.**

**BUTALBITAL, ACETAMINOPHEN
AND CAFFEINE TABLETS, USP
50 mg/325 mg/40 mg**

BOXED WARNING

Hepatotoxicity

Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one acetaminophen-containing product.

DESCRIPTION


Butalbital, Acetaminophen and Caffeine Tablets, USP are supplied in tablet form for oral administration.

Each tablet contains the following active ingredients:


butalbital, USP	50 mg
acetaminophen, USP	325 mg
caffeine, USP	40 mg

*Inactive Ingredients:*silicon dioxide, crospovidone, magnesium stearate, microcrystalline cellulose, povidone, pregelatinized starch, and stearic acid.


Butalbital (5-allyl-5-isobutylbarbituric acid), is a short to intermediate-acting barbiturate. It has the following structural formula:



Acetaminophen (4'-hydroxyacetanilide), is a non-opiate, non-salicylate analgesic and antipyretic. It has the following structural formula:



Caffeine (1,3,7-trimethylxanthine), is a central nervous system stimulant. It has the following structural formula:



CLINICAL PHARMACOLOGY

This combination drug product is intended as a treatment for tension headache.

It consists of a fixed combination of butalbital, acetaminophen and caffeine. The role each component plays in the relief of the complex of symptoms known as tension headache is incompletely understood.

Pharmacokinetics

The behavior of the individual components is described below.

Butalbital

Butalbital is well absorbed from the gastrointestinal tract and is expected to distribute to most tissues in the body. Barbiturates in general may appear in breast milk and readily cross the placental barrier. They are bound to plasma and tissue proteins to a varying degree and binding increases directly as a function of lipid solubility.

Elimination of butalbital is primarily via the kidney (59% to 88% of the dose) as unchanged drug or metabolites. The plasma half-life is about 35 hours. Urinary excretion products include parent drug (about 3.6% of the dose), 5-isobutyl-5-(2, 3-dihydroxypropyl) barbituric acid (about 24% of the dose), 5-allyl-5(3-hydroxy-2-methyl-1-propyl) barbituric acid (about 4.8% of the dose), products with the barbituric acid ring hydrolyzed with excretion of urea (about 14% of the dose), as well as unidentified materials. Of the material excreted in the urine, 32% is conjugated.

The *in vitro* plasma protein binding of butalbital is 45% over the concentration range of 0.5–20 mcg/mL. This falls within the range of plasma protein binding (20%–45%) reported with other barbiturates such as phenobarbital, pentobarbital, and secobarbital sodium. The plasma-to-blood concentration ratio was almost unity, indicating that there is no preferential distribution of butalbital into either plasma or blood cells.

See OVERDOSAGE for toxicity information.

Acetaminophen

Acetaminophen is rapidly absorbed from the gastrointestinal tract and is distributed throughout most body tissues. The plasma half-life is 1.25 to 3 hours, but may be increased by liver damage and following overdosage. Elimination of acetaminophen is principally by liver metabolism (conjugation) and subsequent renal excretion of metabolites. Approximately 85% of an oral dose appears in the urine within 24 hours of administration, most as the glucuronide conjugate, with small amounts of other conjugates and unchanged drug.

See OVERDOSAGE for toxicity information.

Caffeine

Like most xanthines, caffeine is rapidly absorbed and distributed in all body tissues and fluids, including the CNS, fetal tissues, and breast milk.

Caffeine is cleared through metabolism and excretion in the urine. The plasma half-life is about 3 hours. Hepatic biotransformation prior to excretion results in about equal amounts of 1-methylxanthine and 1-methyluric acid. Of the 70% of the dose that is recovered in the urine, only 3% is unchanged drug.

See OVERDOSAGE for toxicity information.

INDICATIONS AND USAGE

Butalbital, acetaminophen and caffeine tablets are indicated for the relief of the symptom complex of tension (or muscle contraction) headache.

Evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable.

CONTRAINDICATIONS

This product is contraindicated under the following conditions:

- Hypersensitivity or intolerance to any component of this product
- Patients with porphyria.

WARNINGS

Hepatotoxicity

Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one acetaminophen-containing product. The excessive intake of acetaminophen may be intentional to cause self-harm or unintentional as patients attempt to obtain more pain relief or unknowingly take other acetaminophen-containing products.

The risk of acute liver failure is higher in individuals with underlying liver disease and in individuals who ingest alcohol while taking acetaminophen.

Instruct patients to look for acetaminophen or APAP on package labels and not to use more than one product that contains acetaminophen. Instruct patients to seek medical attention immediately upon ingestion of more than 4000 milligrams of acetaminophen per day, even if they feel well.

Serious skin reactions

Rarely, acetaminophen may cause serious skin reactions such as acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. Patients should be informed about the signs of serious skin reactions, and use of the drug should be discontinued at the first appearance of skin rash or any other sign of hypersensitivity.

Hypersensitivity/anaphylaxis

There have been post-marketing reports of hypersensitivity and anaphylaxis associated with use of acetaminophen. Clinical signs included swelling of the face, mouth, and throat, respiratory distress, urticaria, rash, pruritus, and vomiting. There were infrequent reports of life-threatening anaphylaxis requiring emergency medical attention. Instruct patients to discontinue Butalbital, Acetaminophen and Caffeine Tablets, USP immediately and seek medical care if they experience these symptoms. Do not prescribe Butalbital, Acetaminophen and Caffeine Tablets, USP for patients with acetaminophen allergy.

Butalbital is habit-forming and potentially abusable. Consequently, the extended use of this product is not recommended.

PRECAUTIONS

General

Butalbital, acetaminophen and caffeine tablets should be prescribed with caution in certain special-risk patients, such as the elderly or debilitated, and those with severe impairment of renal or hepatic function, or acute abdominal conditions.

Information for Patients/Caregivers

- Do not take Butalbital, Acetaminophen and Caffeine Tablets, USP if you are allergic to any of its ingredients.
- If you develop signs of allergy such as a rash or difficulty breathing stop taking Butalbital, Acetaminophen and Caffeine Tablets, USP and contact your healthcare provider immediately.
- Do not take more than 4000 milligrams of acetaminophen per day. Call your doctor if you took more than the recommended dose.

This product may impair mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. Such tasks should be avoided while taking this product.

Alcohol and other CNS depressants may produce an additive CNS depression, when

taken with this combination product, and should be avoided.

Butalbital may be habit-forming. Patients should take the drug only for as long as it is prescribed, in the amounts prescribed, and no more frequently than prescribed.

For information on use in geriatric patients, see *PRECAUTIONS/Geriatric Use*.

Laboratory Tests

In patients with severe hepatic or renal disease, effects of therapy should be monitored with serial liver and/or renal function tests.

Drug Interactions

The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors.

Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.

Drug/Laboratory Test Interactions

Acetaminophen may produce false-positive test results for urinary 5-hydroxyindoleacetic acid.

Carcinogenesis, Mutagenesis, Impairment of Fertility

No adequate studies have been conducted in animals to determine whether acetaminophen or butalbital have a potential for carcinogenesis, mutagenesis or impairment of fertility.

Pregnancy

Teratogenic Effects

Pregnancy Category C

Animal reproduction studies have not been conducted with this combination product. It is also not known whether butalbital, acetaminophen and caffeine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. This product should be given to a pregnant woman only when clearly needed.

Nonteratogenic Effects

Withdrawal seizures were reported in a two-day-old male infant whose mother had taken a butalbital-containing drug during the last two months of pregnancy. Butalbital was found in the infant's serum. The infant was given phenobarbital 5 mg/kg, which was tapered without further seizure or other withdrawal symptoms.

Nursing Mothers

Caffeine, barbiturates and acetaminophen are excreted in breast milk in small amounts, but the significance of their effects on nursing infants is not known. Because of potential for serious adverse reactions in nursing infants from butalbital, acetaminophen and caffeine, a decision should be made whether to discontinue nursing or to discontinue

the drug, taking into account the importance of the drug to the mother.

Pediatric Use

Safety and effectiveness in pediatric patients below the age of 12 have not been established.

Geriatric Use

Clinical studies of butalbital, acetaminophen and caffeine tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Butalbital is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

ADVERSE REACTIONS

Frequently Observed

The most frequently reported adverse reactions are drowsiness, lightheadedness, dizziness, sedation, shortness of breath, nausea, vomiting, abdominal pain, and intoxicated feeling.

Infrequently Observed

All adverse events tabulated below are classified as infrequent.

Central Nervous System: headache, shaky feeling, tingling, agitation, fainting, fatigue, heavy eyelids, high energy, hot spells, numbness, sluggishness, seizure. Mental confusion, excitement, or depression can also occur due to intolerance, particularly in elderly or debilitated patients, or due to overdose of butalbital.

Autonomic Nervous System: dry mouth, hyperhidrosis.

Gastrointestinal: difficulty swallowing, heartburn, flatulence, constipation.

Cardiovascular: tachycardia.

Musculoskeletal: leg pain, muscle fatigue.

Genitourinary: diuresis.

Miscellaneous: pruritus, fever, earache, nasal congestion, tinnitus, euphoria, allergic reactions.

Several cases of dermatological reactions, including toxic epidermal necrolysis and erythema multiforme, have been reported.

The following adverse drug events may be borne in mind as potential effects

of the components of this product. Potential effects of high dosage are listed in the OVERDOSAGE section.

Acetaminophen: allergic reactions, rash, thrombocytopenia, agranulocytosis.

Caffeine: cardiac stimulation, irritability, tremor, dependence, nephrotoxicity, hyperglycemia.

To report SUSPECTED ADVERSE REACTIONS, contact Westminster Pharmaceuticals, LLC at 1-844-221-7294 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG ABUSE AND DEPENDENCE

Abuse and Dependence

Butalbital

Barbiturates may be habit-forming

Tolerance, psychological dependence, and physical dependence may occur especially following prolonged use of high doses of barbiturates. The average daily dose for the barbiturate addict is usually about 1500 mg. As tolerance to barbiturates develops, the amount needed to maintain the same level of intoxication increases; tolerance to a fatal dosage, however, does not increase more than two-fold. As this occurs, the margin between an intoxication dosage and fatal dosage becomes smaller. The lethal dose of a barbiturate is far less if alcohol is also ingested. Major withdrawal symptoms (convulsions and delirium) may occur within 16 hours and last up to 5 days after abrupt cessation of these drugs. Intensity of withdrawal symptoms gradually declines over a period of approximately 15 days. Treatment of barbiturate dependence consists of cautious and gradual withdrawal of the drug. Barbiturate-dependent patients can be withdrawn by using a number of different withdrawal regimens. One method involves initiating treatment at the patient's regular dosage level and gradually decreasing the daily dosage as tolerated by the patient.

OVERDOSAGE

Following an acute overdosage of butalbital, acetaminophen and caffeine, toxicity may result from the barbiturate or the acetaminophen. Toxicity due to caffeine is less likely, due to the relatively small amounts in this formulation.

Signs and Symptoms

Toxicity from **barbiturate** poisoning includes drowsiness, confusion, and coma; respiratory depression; hypotension; and hypovolemic shock.

In **acetaminophen** overdosage: dose-dependent, potentially fatal hepatic necrosis is the most serious adverse effect. Renal tubular necroses, hypoglycemic coma and coagulation defects may also occur. Early symptoms following a potentially hepatotoxic overdose may include: nausea, vomiting, diaphoresis and general malaise. Clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours post-ingestion.

Acute **caffeine** poisoning may cause insomnia, restlessness, tremor, and delirium, tachycardia and extrasystoles.

Treatment

A single or multiple drug overdose with this combination product is a potentially lethal polydrug overdose, and consultation with a regional poison control center is recommended. Immediate treatment includes support of cardiorespiratory function and measures to reduce drug absorption.

Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Assisted or controlled ventilation should also be considered.

Gastric decontamination with activated charcoal should be administered just prior to N-acetylcysteine (NAC) to decrease systemic absorption if acetaminophen ingestion is known or suspected to have occurred within a few hours of presentation. Serum acetaminophen levels should be obtained immediately if the patient presents 4 hours or more after ingestion to assess potential risk of hepatotoxicity; acetaminophen levels drawn less than 4 hours post-ingestion may be misleading. To obtain the best possible outcome, NAC should be administered as soon as possible where impending or evolving liver injury is suspected. Intravenous NAC may be administered when circumstances preclude oral administration.

Vigorous supportive therapy is required in severe intoxication. Procedures to limit the continuing absorption of the drug must be readily performed since the hepatic injury is dose dependent and occurs early in the course of intoxication.

DOSAGE AND ADMINISTRATION

One or two tablets every four hours as needed. Total daily dosage should not exceed 6 tablets.

Extended and repeated use of this product is not recommended because of the potential for physical dependence.

HOW SUPPLIED

Butalbital, Acetaminophen, and Caffeine Tablets USP, 50 mg/325 mg/40 mg

Tablet containing 50 mg butalbital, 325 mg acetaminophen, and 40 mg caffeine. Available as white to off-white round tablets, debossed "BAC" on one side and debossed "123" on the other side.

- Bottles of 10 tablets (NDC 76420-802-10 repackaged from NDC 69367-203-XX)
- Bottles of 12 tablets (NDC 76420-802-12 repackaged from NDC 69367-203-XX)
- Bottles of 20 tablets (NDC 76420-802-20 repackaged from NDC 69367-203-XX)
- Bottles of 30 tablets (NDC 76420-802-30 repackaged from NDC 69367-203-XX)
- Bottles of 60 tablets (NDC 76420-802-60 repackaged from NDC 69367-203-XX)
- Bottles of 90 tablets (NDC 76420-802-90 repackaged from NDC 69367-203-XX)
- Bottles of 100 tablets (NDC 76420-802-01 relabeled from NDC 69367-203-01)
- Bottles of 500 tablets (NDC 76420-802-05 relabeled from NDC 69367-203-05)

Relabeled and Repackaged by:
Enovachem PHARMACEUTICALS
Torrance, CA 90501

PRINCIPAL DISPLAY PANEL -

Packaged By: **Enovachem**
PHARMACEUTICALS
 379 Van Ness Ave.
 Suite 100-100
 Torrance, CA 90501

Butalbital, APAP, and Caffeine Tablets, USP 50mg/325mg/40mg

NDC: 76420-802-10
 Qty: 10
 Manufactured For: Westminster Pharmaceuticals, LLC
 Source NDC: 69387-203-XX
 Description: white, off-white, round tablets/debossed, BAC/123
 Lot #: XXXXXXXXXX
 Exp: **CHII**
 Batch #: XXXXXXXXXX
 Drug Status: CIII

(01) 6 0376420 80210 5
 (17)
 000000000000
 (21)

CAUTION: FEDERAL LAW PROHIBITS DISPENSING WITHOUT PRESCRIPTION. SEE PACKAGE INSERT.
 KEEP OPEN STORE AT ALL TIMES. DO NOT USE IF CONTAINER IS BROKEN.

Subtotal: APAP, and Caffeine Tablets, USP 50mg/325mg/40mg
NDC: 76420-802-10
S/N:
Qty: 10 CIII

Subtotal: APAP, and Caffeine Tablets, USP 50mg/325mg/40mg
NDC: 76420-802-10
S/N:
Qty: 10 CIII

Subtotal: APAP, and Caffeine Tablets, USP 50mg/325mg/40mg
NDC: 76420-802-10
S/N:
Qty: 10 CIII

Packaged By:

 **Enovachem**
PHARMACEUTICALS

Butalbital, APAP, and Caffeine Tablets, USP 50mg/325mg/40mg

379 Van Ness Ave.
Suite 1627-1650
Torrance, CA 90501

NDC: 76420-802-90
Qty: 90
Manufactured For: Westminster Pharmaceuticals, LLC
Source NDC: 06307-203-X
Description: white to off-white, round tablets/debossed, BAC/123
Lot #: XXXXXXXXXX Exp: **CHII**
Batch #: XXXXXXXXX
Drug Status: CIII

 (01) 05187420 902907
(17)
(01) XXXXXXXXXX
(21)

CAUTION: FEDERAL LAW PROHIBITS DISPENSING WITHOUT PRESCRIPTION. SEE PACKAGE INSERT FOR FULL DIRECTIONS AND INFORMATION.

Busulfan, APAP, and Cefixime Tablets, USP 50mg/325mg/400mg

NDC: 76420-802-60

S/N:

Qty: 90

CIII

Busulfan, APAP, and Cefixime Tablets, USP 50mg/325mg/400mg

NDC: 76420-802-60

S/N:

Qty: 90

CIII

Busulfan, APAP, and Cefixime Tablets, USP 50mg/325mg/400mg

NDC: 76420-802-60

S/N:

Qty: 90

CIII

Packaged By:



Enovachem
PHARMACEUTICALS
Subsalicyl, APAP, and Caffeine Tablets, USP 50mg/325mg/40mg

379 Van Ness Ave.
Suite 1403-1406
Torrance, CA 90501

NDC: 76420-802-12
Qty: 12
Manufactured For: Westminster Pharmaceuticals, LLC
Source NDC: 069367-203-X
Description: white to off-white round tablets/debossed, BAC 123
Lot #: XXXXXXXXXX
Batch #: XXXXXXXXXX
Drug Status: CIII



(0) 02574-20 002-12
(1) 02574-20 002-12
(21)

CAUTION: FEDERAL LAW PROHIBITS DISPENSING WITHOUT PRESCRIPTION. SEE PACKAGE INSERT.

Subtotal: APAP, and Caffeine Tablets, USP 50mg/325mg/40mg	
NDC: 76420-802-12	
S/N:	
Qty: 12	CIII
Subtotal: APAP, and Caffeine Tablets, USP 50mg/325mg/40mg	
NDC: 76420-802-12	
S/N:	
Qty: 12	CIII
Subtotal: APAP, and Caffeine Tablets, USP 50mg/325mg/40mg	
NDC: 76420-802-12	
S/N:	
Qty: 12	CIII

Relabeled By:

 **Enovachem**
NANOMEDICALS
Butabulol, APAP, and Caffeine Tablets, USP 50mg/325mg/40mg

379 Van Ness Ave.
Suite 1403-1406
Toronto, CA 95001
USF 50mg/325mg/40mg



(01) 01574-020021 3

NDC: 76420-802-01
Qty: 100
Manufactured For: Westminster Pharmaceuticals, LLC
Source NDC: 69397-2031
Description: White to off-white round tablets/debossed, BAC-123
Lot #: XXXXXXXXX Exp: **CIII**
Batch #: XXXXXXXXX
Drug Status: CIII

CAUTION: FEDERAL LAW PROHIBITS DISPENSING WITHOUT PRESCRIPTION. SEE PACKAGE INSERT FOR FULL LIST OF WARNINGS. STORE AT 20-25°C (68-77°F) USE USP CONTROLLED ROOM TEMP.

Substitol, ADAP, and Caffeine Tablets, USP 50mg/325mg/40mg
NDC: 76420-802-01
S/N: CIII
Qty: 100

Substitol, ADAP, and Caffeine Tablets, USP 50mg/325mg/40mg
NDC: 76420-802-01
S/N: CIII
Qty: 100

Substitol, ADAP, and Caffeine Tablets, USP 50mg/325mg/40mg
NDC: 76420-802-01
S/N: CIII
Qty: 100

Packaged By:



Enovachem
PHARMACEUTICALS

Butalbital, APAP, and Caffeine Tablets, USP 50mg/325mg/40mg

379 Van Ness Ave.
Suite 303-25
Torrance, CA 90501

NDC: 76420-802-20
Qty: 20

Manufacturer For: Westminster Pharmaceuticals, LLC
Source NDC: 80207-200-XX
Description: white to off-white round tablets/debossed; BAC/123
Lot #: XXXXXXXXX Exp: _____
Batch #: XXXXXXXXX
Drug Status: CIII



(01) 6 01376420 80220 4
(17)
XXXXXXXXXXXX
(21)

CIII

CAUTION: FEDERAL LAW PROHIBITS DISPENSING WITHOUT PRESCRIPTION. SEE PACKAGE INSERT FOR INFORMATION ON CILINDRICAL STORAGE AT 25°C (77°F) (USE UNCONTROLLED ROOM TEMP.

Subtotal: APAP, and Caffeine Tablets, USP 50mg/325mg/ginger NDC: 76420-802-20 S/N: Qty. 20	CIII
Subtotal: APAP, and Caffeine Tablets, USP 50mg/325mg/ginger NDC: 76420-802-20 S/N: Qty. 20	CIII
Subtotal: APAP, and Caffeine Tablets, USP 50mg/325mg/ginger NDC: 76420-802-20 S/N: Qty. 20	CIII

Relabeled By:
 **Enovachem**
 PHARMACEUTICALS
 379 Van Ness Ave.
 Suite 1403-1406
 Turfway, CA 94501
 Butabital, APAP, and Caffeine Tablets, USP 50mg/325mg/40mg


 NDC: 76420-802-05
 Qty: 500
 Manufactured For: Westminster Pharmaceuticals, LLC
 Source NDC: 86987-203-05
 Description: White to off-white round tablets/debossed, BAC 123
 Lot #: XXXXXXXXX Exp: **CIII**
 Batch #: XXXXXXXXX
 Drug Status: CIII


 (0) 01674-02 0025 1
 (1) 00 XXXXXXXXX
 (2)

CAUTION: FEDERAL LAW PROHIBITS DISPENSING WITHOUT PRESCRIPTION. SEE PACKAGE INSERT FOR FULL LIST OF CAUTIONS, STORAGE, AND DOSAGE. (05-1774) USE CONTROL (R) 05/01/2017

Susbital, AFAP, and Caffeine Tablets, USP 50mg/325mg/60mg
NDC: 76420-802-05
S/N:
Qty: 500 CIII

Susbital, AFAP, and Caffeine Tablets, USP 50mg/325mg/60mg
NDC: 76420-802-05
S/N:
Qty: 500 CIII

Susbital, AFAP, and Caffeine Tablets, USP 50mg/325mg/60mg
NDC: 76420-802-05
S/N:
Qty: 500 CIII

Packaged By:



Enovachem
PHARMACEUTICALS
Subaltilal, APAP, and Caffeine Tablets, USP 50mg/325mg/40mg

379 Van Ness Ave.
Suite 203
Toronto, CA 90501

NDC: 76420-802-30
Qty: 30

Manufactured For: Westminster Pharmaceuticals, LLC
Source NDC: 86367-203-X
Description: white to off-white round tablets/debossed, BAC/123
Lot #: XXXXXXXXXX Exp: XXXXXXXXXX
Batch #: XXXXXXXXXX CIII
Drug Status: CIII



(01) 6 0376420 80230 3
(17)
XXXXXXXXXXXX
(21)

CAUTION: FEDERAL LAW PROHIBITS DISPENSING WITHOUT PRESCRIPTION. SEE PACKAGE INSERT FOR OPEN STORE AT 20°C (68°F) [USE US CONTROLLED SUBSTANCE]

Subtotal: APAP, and Caffeine Tablets, USP 500mg/325mg/65mg
NDC: 76420-802-30
S/N:
Qty. 30 CIII

Subtotal: APAP, and Caffeine Tablets, USP 500mg/325mg/65mg
NDC: 76420-802-30
S/N:
Qty. 30 CIII

Subtotal: APAP, and Caffeine Tablets, USP 500mg/325mg/65mg
NDC: 76420-802-30
S/N:
Qty. 30 CIII

Packaged By: **Enovachem**
PHARMACEUTICALS
 Butalbital, APAP, and Caffeine Tablets, USP 50mg/325mg/40mg

379 Van Ness Ave.
 Suite 100-10
 Torrance, CA 90501

NDC: 76420-802-60
 Qty: 60

Manufactured For: Westminster Pharmaceuticals, LLC
 Source NDC: 06967-203-X
 Description: white to off-white round tablets/debossed; BAC/123
 Lot #: XXXXXXXXXX
 Exp: _____
 Batch #: XXXXXXXXXX
 Drug Status: CIII

CAUTION: FEDERAL LAW PROHIBITS DISPENSING WITHOUT PRESCRIPTION. SEE PACKAGE INSERT.
 KEEP CHILDREN STORED AT 20-25°C (68-77°F) (USE US CONTROLLED SUBSTANCE ACT)

Subtotal: APAP, and Caffeine Tablets, USP 50mg/325mg/65mg
NDC: 76420-802-60
S/N:
Qty: 60 CIII

Subtotal: APAP, and Caffeine Tablets, USP 50mg/325mg/65mg
NDC: 76420-802-60
S/N:
Qty: 60 CIII

Subtotal: APAP, and Caffeine Tablets, USP 50mg/325mg/65mg
NDC: 76420-802-60
S/N:
Qty: 60 CIII

BUTALBITAL, ACETAMINOPHEN, CAFFEINE

butalbital, acetaminophen, and caffeine tablet

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:76420- 802(NDC:69367-203)
---------------------	----------------------------	---------------------------	----------------------------------

Route of Administration	ORAL	DEA Schedule	CIII
--------------------------------	------	---------------------	------

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
BUTALBITAL (UNII: KHS0AZ4JVK) (BUTALBITAL - UNII:KHS0AZ4JVK)	BUTALBITAL	50 mg
ACETAMINOPHEN (UNII: 362O9ITL9D) (ACETAMINOPHEN - UNII:362O9ITL9D)	ACETAMINOPHEN	325 mg
CAFFEINE (UNII: 3G6A5W338E) (CAFFEINE - UNII:3G6A5W338E)	CAFFEINE	40 mg

Inactive Ingredients

Ingredient Name	Strength
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)	
CROSPVIDONE (UNII: 2S7830E561)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	
MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)	
POVIDONE, UNSPECIFIED (UNII: FZ989GH94E)	
STEARIC ACID (UNII: 4ELV7Z65AP)	

Product Characteristics

Color	white	Score	no score
Shape	ROUND	Size	12mm
Flavor		Imprint Code	BAC;123
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:76420-802-10	10 in 1 BOTTLE; Type 0: Not a Combination Product	04/29/2024	
2	NDC:76420-802-12	12 in 1 BOTTLE; Type 0: Not a Combination Product	04/29/2024	
3	NDC:76420-802-20	20 in 1 BOTTLE; Type 0: Not a Combination Product	04/29/2024	
4	NDC:76420-802-30	30 in 1 BOTTLE; Type 0: Not a Combination Product	04/29/2024	
5	NDC:76420-802-60	60 in 1 BOTTLE; Type 0: Not a Combination Product	04/29/2024	
6	NDC:76420-802-90	90 in 1 BOTTLE; Type 0: Not a Combination Product	04/29/2024	
7	NDC:76420-802-01	100 in 1 BOTTLE; Type 0: Not a Combination Product	04/29/2024	
8	NDC:76420-802-05	500 in 1 BOTTLE; Type 0: Not a Combination Product	04/29/2024	

Marketing Information

Marketing	Application Number or Monograph	Marketing Start	Marketing End
------------------	--	------------------------	----------------------

Category	Citation	Date	Date
ANDA	ANDA209587	03/05/2019	

Labeler - Asclemed USA, Inc. (059888437)

Establishment

Name	Address	ID/FEI	Business Operations
ASCLEMED USA INC. DBA ENOVACHEM		059888437	relabel(76420-802) , repack(76420-802)

Revised: 11/2025 Asclemed USA, Inc.